Donate

FOLFIRINOX

Medicine bottlesFOLFIRINOX is a combination of five chemotherapy agents and is used in the UK for patients with metastatic (spread to other parts of the body) pancreatic cancer, locally advanced (inoperable but not spread elsewhere) pancreatic cancer and occasionally used as a neo-adjuvant (before surgery) agent to try to shrink a tumour for surgical removal to be possible.

FOLFIRINOX started as a clinical trial where a combination of the chemotherapy drugs fluorouracil [5-FU], leucovorin, irinotecan and oxaliplatin or standard single-drug treatment, gemcitabine. were given to patients with metastatic pancreatic cancer.

Patients in the FOLFIRINOX arm received oxaliplatin (85 mg/m2 over two hours), leucovorin (400 mg/m2 over two hours), irinotecan (180 mg/m2 over 90 minutes), and 5-FU(400 mg/m2 bolus then 2,400 mg/m2 over 46 hours), all on day 1, and then repeated every two weeks. Patients in the control arm received gemcitabine (1,000 mg/m2 IV over 30 minutes weekly for seven of eight weeks, one week rest, and then weekly for three of four weeks). Recent results from this french study have shown this combination is promising.

The study’s authors1, presenting at ASCO 2010, reported 48% of patients on FOLFIRINOX were alive after 1 year compared to 20% on the gemcitabine arm and, for the first time in a study involving patients with metastatic pancreatic cancer, a median overall survival of 11.1 months was obtained on the FOLFIRINOX arm.

FOLFIRINOX is not approved by either NICE (National Institute of Clinical Excellence) in England and Wales nor the SMC (Scottish Medicines Consortium) for pancreatic cancer so is not available as standard treatment for pancreatic cancer.

Some centres in the UK will offer FOLFIRINOX to  pancreatic cancer patients if they get approval from the PCT (Primary Care Trust)

However, the FOLFIRINOX  regime can be very toxic and side effects can be greater than the standard therapy – so it is not suitable for all patients. 

To find out if you are eligible for any current clinical trials in the UK, speak to your oncologist or click here to see a list of pancreatic cancer clinical trials

Typical FOLFIRINOX treatment

The treatment will usually consist of the following:

This treatment is repeated every 2 weeks for a total of 6 to 12 cycles.

 FOLFIRINOX SIDe Effects:

The side effects of a combination of drugs are usually a mixture of those of each individual drug. It has been found that more than one in ten people will have one or more of the following side effects:

 It is important you tell your medical team if you have any of the above side effects, especially if you develop a temperature above 38oC.

Other common side effects include:

Occasional Side Effects:

 Rare Side effects:

Remember—you will not have all of the side effects listed here. You may only have 1 or 2 or several. Talk to your medical team if you are experiencing any form of side effect while on FOLFIRINOX chemotherapy treatment.

Infections can be serious. Let your doctor or nurse know immediately if your temperature goes above 38o C (100.4o F) or you suddenly feel unwell even with a normal temperature.

 Other FOLFIRINOX-type Combinations:

FOLFIRI (Folinic Acid, Fluorouracil (5FU), Irinotecan)

FOLFOX (Folinic Acid, Fluorouracil (5-FU), Oxaliplatin

These regimes are similar to the FOLFIRINOX treatment but without the Oxaliplatin for FOLFIRI and without the Irinotecan for the FOLFOX regime

Treatment will usually consist of the following:

This treatment is repeated every two weeks for a total of 6 or 12 cycles

 

Footnotes:

  1. Conroy et al., (2010) Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J. Clin Oncol 28: 303s 

The information provided in this site, or through links to other websites, is not a substitute for medical or professional care and should not be relied upon as such. Read our disclaimer.